NCT05365178 2026-01-07
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Active not recruiting